17.81
0.06%
-0.01
Avadel Pharmaceuticals plc ADR stock is currently priced at $17.81, with a 24-hour trading volume of 452.41K.
It has seen a -0.06% decreased in the last 24 hours and a +9.67% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $17.54 pivot point. If it approaches the $18.14 resistance level, significant changes may occur.
Previous Close:
$17.82
Open:
$17.85
24h Volume:
452.41K
Market Cap:
$1.61B
Revenue:
$47.56M
Net Income/Loss:
$-160.28M
P/E Ratio:
-8.5625
EPS:
-2.08
Net Cash Flow:
$-128.51M
1W Performance:
+2.77%
1M Performance:
+9.67%
6M Performance:
+83.61%
1Y Performance:
+77.39%
Avadel Pharmaceuticals plc ADR Stock (AVDL) Company Profile
Name
Avadel Pharmaceuticals plc ADR
Sector
Phone
353 1 485 1200
Address
Block 10-1, Blanchardstown Corporate Park Ballycoolin, Dublin
Avadel Pharmaceuticals plc ADR Stock (AVDL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-06-24 | Initiated | UBS | Buy |
Nov-30-22 | Upgrade | Jefferies | Hold → Buy |
Aug-10-22 | Downgrade | Jefferies | Buy → Hold |
Jul-28-22 | Resumed | Craig Hallum | Buy |
May-26-22 | Downgrade | Stifel | Buy → Hold |
Sep-23-21 | Initiated | Needham | Buy |
Jul-31-20 | Initiated | Oppenheimer | Outperform |
Jul-21-20 | Initiated | SVB Leerink | Outperform |
Jun-30-20 | Initiated | H.C. Wainwright | Buy |
Apr-03-20 | Initiated | Jefferies | Buy |
Mar-12-20 | Initiated | Stifel | Buy |
Feb-26-20 | Initiated | Piper Sandler | Overweight |
Jan-30-20 | Initiated | Craig Hallum | Buy |
Jun-14-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Feb-08-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
View All
Avadel Pharmaceuticals plc ADR Stock (AVDL) Latest News
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
GlobeNewswire Inc.
American Airlines To Rally Around 42%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga
Avadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
Benzinga
Avadel Pharmaceuticals Issues Statement On Patent Litigation
GlobeNewswire Inc.
Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Here's Why You Should Invest in Avadel (AVDL) Stock Now
Zacks Investment Research
Avadel Pharmaceuticals plc ADR Stock (AVDL) Financials Data
Avadel Pharmaceuticals plc ADR (AVDL) Revenue 2024
AVDL reported a revenue (TTM) of $47.56 million for the quarter ending June 30, 2020.
Avadel Pharmaceuticals plc ADR (AVDL) Net Income 2024
AVDL net income (TTM) was -$160.28 million for the quarter ending December 31, 2023, a -16.59% decrease year-over-year.
Avadel Pharmaceuticals plc ADR (AVDL) Cash Flow 2024
AVDL recorded a free cash flow (TTM) of -$128.51 million for the quarter ending December 31, 2023, a -80.95% decrease year-over-year.
Avadel Pharmaceuticals plc ADR (AVDL) Earnings per Share 2024
AVDL earnings per share (TTM) was -$2.01 for the quarter ending December 31, 2023, a +12.23% growth year-over-year.
About Avadel Pharmaceuticals plc ADR
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Cap:
|
Volume (24h):